News
-
SynRx's SYN818 in Combination with Olapa...
Designation supports accelerated development of a Polθ inhibitor-PARP inhibitor combination for germline BRCA-mutated, HER2-negative breast cancer
MORE -
SynRx Therapeutics presents data on the ...
SynRx Therapeutics announces the presentation of its PARG inhibitor program at at the 36th EORTC-NCI-AACR Symposium
MORE -
A Best-in-Class Polθ Inhibitor SYN818 fr...
A Best-in-Class Polθ Inhibitor SYN818 from SynRx Therapeutics Received IND Clearance from U.S. FDA
MORE -
AACR Annual Meeting 2024 grandly opens, ...
April 5, AACR Annual Meeting (AACR 2024) opened at the San Diego Convention Center, San Diego, California. SynRx Therapeutics attended the meeting and presented the latest preclinical data from the project in the form of posters.
MORE
